Acasti Appoints Seasoned Executive Brian D. Ford CPA-CA as Chief Financial Officer
September 16 2020 - 6:55AM
Acasti Pharma Inc. (“
Acasti” or the
“
Company”) (NASDAQ: ACST – TSX-V: ACST) announced
that it has appointed seasoned financial executive Brian D. Ford as
its Chief Financial Officer, effective September 14, 2020. Mr. Ford
assumes the responsibilities formerly held by Jean-Francois Boily,
Vice-President, Finance, who recently resigned.
Brian D. Ford brings over three decades of
financial, project management and M&A experience within the
healthcare and financial industries. Mr. Ford is an accomplished
CPA-CA having served both publicly traded as well as privately
owned organizations. Mr. Ford has been responsible for developing
business recovery strategies, negotiating M&A transactions, as
well as managing quarterly and yearly accounting reports. Most
recently, Mr. Ford served as Chief Financial Officer and Senior
Business Advisor at a private group of Ontario based medical
clinics, including the largest chronic pain management practice in
Canada. During his position as CFO and Senior Business Advisor, Mr.
Ford significantly improved the Company’s performance and was
instrumental in preparing the Company for its Initial Public
Offering. Prior to that, Mr. Ford served as Chief Financial Officer
at Telesta Therapeutics. At Telesta Therapeutics, Mr. Ford helped
develop a new business plan and was heavily involved in all capital
transactions. Previously, Mr. Ford started his own consulting firm,
Petersford Consulting, where he provided clients with finance and
business risk services. Mr. Ford began his career at Ernst &
Young, working his way to Principal, Business Risk Services,
developing essential business plans that evaluated revenue and cost
profiles supporting budget planning and understanding drivers of
growth, specifically with healthcare companies. Additionally, at
Ernst & Young, Mr. Ford participated in and often led teams in
due diligence assignments in relation to mergers and acquisitions
or the sale of a business, having extensive experience in
developing financial forecasts, product and market valuation, and
audits of critical accounting and processes. Mr. Ford holds a B.A.
in Economics, History, and English from the University of Guelph
and has a Graduate Diploma in Accounting from the University of
McGill. Mr. Ford is a member of the Ontario Institute of Chartered
Accountants.
Jan D’Alvise, Chief Executive Officer of Acasti,
commented, “We are extremely pleased to appoint Brian D. Ford as
Chief Financial Officer. Brian brings strong leadership skills, as
well as analytical and financial skills that we believe will add
significant value. As we explore strategic options and
opportunities, we believe Brian’s experience in problem solving,
strategic transactions, and M&A will prove beneficial. Brian
will assume all responsibilities formerly held by Jean-Francois
Boily, who recently resigned, as previously announced. We thank Mr.
Boily for his contributions to Acasti and wish him well on his
future endeavours.”
Brian D. Ford commented, “I’m thrilled to accept
the CFO position at Acasti Pharma and look forward to successfully
working with the Acasti team. I believe my experience in evaluating
strategic opportunities as well as M&A transactions will
provide valuable insights for Acasti as we evaluate our options
moving forward.”
Forward Looking Statements
Statements in this press release that are not
statements of historical or current fact constitute
“forward-looking information” within the meaning of Canadian
securities laws and “forward-looking statements” within the meaning
of U.S. federal securities laws (collectively, “forward-looking
statements”). Such forward-looking statements involve known and
unknown risks, uncertainties, and other unknown factors that could
cause the actual results of Acasti to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are urged
to consider statements labeled with the terms “believes,” “belief,”
“expects,” “intends,” “anticipates,” “potential,” “should,” “may,”
“will,” “plans,” “continue”, “targeted” or other similar
expressions to be uncertain and forward-looking. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
Forward-looking statements in this press release include, but are
not limited to, information or statements about Acasti’s strategy,
future operations, its review of strategic options, potential value
for CaPre®, prospects and the plans of management.
The forward-looking statements contained in this
press release are expressly qualified in their entirety by this
cautionary statement, the “Special Note Regarding Forward-Looking
Statements” section contained in Acasti’s latest annual report on
Form 10-K, which will be available on EDGAR
at www.sec.gov/edgar/shtml, on SEDAR
at www.sedar.com and on the investor section of Acasti’s
website at www.acastipharma.com. All forward-looking
statements in this press release are made as of the date of this
press release. Acasti does not undertake to update any such
forward-looking statements whether as a result of new information,
future events or otherwise, except as required by law. The
forward-looking statements contained herein are also subject
generally to assumptions and risks and uncertainties that are
described from time to time in Acasti’s public securities filings
with the Securities and Exchange Commission and the Canadian
securities commissions, including Acasti’s latest annual report on
Form 10-K under the caption “Risk Factors”.
Neither NASDAQ, the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this
release.
Acasti
Contact:Jan
D’AlviseChief Executive OfficerTel: 450-686-4555Email:
info@acastipharma.comwww.acastipharma.com
Investor
Contact:Crescendo
Communications, LLCTel: 212-671-1020Email:
ACST@crescendo-ir.com
Acasti Pharma (NASDAQ:ACST)
Historical Stock Chart
From Aug 2024 to Sep 2024
Acasti Pharma (NASDAQ:ACST)
Historical Stock Chart
From Sep 2023 to Sep 2024